Topics

Dendreon Corporation
FDA approves immune-boosting therapy for prostate cancer
FDA approves immune-boosting therapy for prostate cancer

The Food and Drug Administration approved a new immune-boosting therapy for prostate cancer on Thursday, the first therapeutic vaccine for cancer ever approved by the agency. The approval opens the door to a whole new approach to cancer therapy, adding a unique weapon to the arsenal of oncologists. The vaccine, Provenge, has been shown to extend survival in patients with advanced prostate cancer by four months, more than twice as long as chemotherapy, and to increase three-year survival by 38%. "A lot of people have been working in labs, biotechs and pharma companies looking for a proof of principle" that immunotherapy works against cancer, said Dr. David I. Quinn, medical...

Loading